Patent · US Active

Pharmaceutical composition containing silybin and VE

US12090138B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

TASLY PHARMACEUTICAL GROUP CO., LTD. · CN

Inventors

He Sun · Shanghai, CN
Xijun Yan · Tianjin, CN
Naifeng Wu · Tianjin, CN
Kaijing Yan · Tianjin, CN
Yonghong Zhu · Tianjin, CN
Shunnan Zhang · Tianjin, CN
Xiaolin Bai · Tianjin, CN
Xiaohui Ma · Tianjin, CN
Yi He · Tianjin, CN
Ting Li · Nanhu, CN
Lei Li · Zhengzhou, CN

Key dates

Filing date	Jan 28, 2022
Grant date	Sep 17, 2024
Priority date	—
Expiry date	Jan 26, 2043

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.